Palatin Technologies (PTN)
XASE:PTN
Want to see PTN full AI Analyst Report?
Top Page
Palatin Technologies
(NYSE MKT:PTN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$19.00
▲(18.38% Upside)
Action:Reiterated
Date:05/13/26
The score is held down primarily by weak financial performance—especially heavy, persistent cash burn and ongoing losses—despite low leverage. The earnings call was a relative positive (partner-driven revenue, improved loss profile, and runway guidance), but technical indicators are slightly bearish and valuation is unattractive due to lack of profitability and no dividend support.
Positive Factors
Partnerships & non‑dilutive funding
Material non‑dilutive inflows from Boehringer Ingelheim and a sublicensing upfront reduce near‑term financing pressure, validate the science commercially, and create milestone/royalty upside. These partnership payments materially extend runway and preserve equity for longer‑term value creation.
Negative Factors
Significant cash burn and limited runway
Persistent multi‑year negative operating and free cash flow creates acute funding and dilution risk. With runway only to mid‑2027 under current plans, the company may need more non‑dilutive deals or equity raises, which can force suboptimal timing of programs and constrain strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Partnerships & non‑dilutive funding
Material non‑dilutive inflows from Boehringer Ingelheim and a sublicensing upfront reduce near‑term financing pressure, validate the science commercially, and create milestone/royalty upside. These partnership payments materially extend runway and preserve equity for longer‑term value creation.
Read all positive factors
Palatin Technologies (PTN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$34.92M
Dividend YieldN/A
Average Volume (3M)2.99K
Price to Earnings (P/E)―
Beta (1Y)-0.23
Revenue Growth2461.02%
EPS Growth87.54%
CountryUS
Employees30
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.82
Shares Outstanding1,772,199
10 Day Avg. Volume2,746
30 Day Avg. Volume2,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.18
Enterprise Value/Market Cap14.09
Enterprise Value/Revenue54.91
Enterprise Value/Gross Profit55.33
Enterprise Value/Ebitda-51.46
Forecast
1Y Price Target
$50.00Price Target Upside211.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.24
Revenue Forecast (FY)$11.09M
Palatin Technologies Business Overview & Revenue Model
Company Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for ...
How the Company Makes Money
Palatin historically has generated revenue primarily through collaboration, licensing, and commercialization-related arrangements around its drug candidates, rather than through broad-based product sales. Key revenue sources have included: (1) lic...
Palatin Technologies Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Neutral
Balanced: The call highlighted meaningful near-term commercial validation via upfront collaboration revenue, materially reduced net loss, reduced operating cash burn, strong partnership-driven non-dilutive funding and clear progress across peptide and oral MC4R programs (including IP development). Offsetting these positives are increased operating costs, a limited cash runway to mid-2027 that creates funding risk, a deprioritized earlier oral candidate and timing/competitive risks (notably Rhythm's approved product). Clinical risk around hyperpigmentation and the need for further IND/clinic-readout milestones keep the outlook cautious.Positive Updates
Revenue Recognition and Improved Loss Profile
Recognized $3.9M in collaboration and license revenue in Q3 FY2026 vs $0 in prior year; net loss narrowed to $1.4M (-$0.37 per share) from $4.8M (-$9.13 per share) in the prior year period (net loss improved ~70.8%), driven primarily by upfront collaboration revenue recognition.
Negative Updates
Increase in Operating Expenses
Total operating expenses rose to $5.5M in the quarter from $4.8M in the prior year period (increase of ~$0.7M, ≈14.6%), driven primarily by higher compensation costs and professional fees.
Read all updates
Q3-2026 Updates
Positive
Negative
Revenue Recognition and Improved Loss Profile
Recognized $3.9M in collaboration and license revenue in Q3 FY2026 vs $0 in prior year; net loss narrowed to $1.4M (-$0.37 per share) from $4.8M (-$9.13 per share) in the prior year period (net loss improved ~70.8%), driven primarily by upfront collaboration revenue recognition.
Read all positive updates
Company Guidance
On the call management provided specific financial and programmatic guidance: Q3 FY2026 collaboration and license revenue was $3.9M (vs $0 in the year‑ago period), total operating expenses were $5.5M (vs $4.8M, which included a $0.4M gain on purchase commitment), net cash used in operations was $4.4M (down from $5.4M), and net loss narrowed to $1.4M (−$0.37 per basic/diluted share) from a $4.8M loss (−$9.13 per share) a year earlier; as of March 31, 2026 Palatin had $10.2M cash and cash equivalents plus approximately $2.2M of receivables expected in the quarter ending June 30, 2026, and believes existing cash plus expected receivables will fund operations through June 30, 2027. Management also highlighted nondilutive inflows (EUR 7.5M, ~ $8.8M, from Boehringer Ingelheim in H2 2025 and a $3.8M Altanispac upfront in Jan 2026), said IND‑enabling studies are underway for the once‑weekly peptide (on track for an initial submission in Q4 calendar 2026) and targeted an IND for next‑generation oral candidates in 1H 2027.Palatin Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Jun 2025 | Sep 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.96M | 0.00 | 4.49M | 4.85M | 1.47M | -188.60K |
| Gross Profit | 8.90M | -258.92K | 4.39M | 4.44M | 1.25M | -336.44K |
| EBITDA | -9.56M | -17.03M | -29.38M | -28.40M | -35.68M | -33.52M |
| Net Income | -9.63M | -17.31M | -29.74M | -24.04M | -36.20M | -33.57M |
Balance Sheet | ||||||
| Total Assets | 17.93M | 3.27M | 10.74M | 17.94M | 36.07M | 67.30M |
| Cash, Cash Equivalents and Short-Term Investments | 14.48M | 2.56M | 9.53M | 10.98M | 29.94M | 60.10M |
| Total Debt | 348.79K | 163.78K | 590.34K | 1.05M | 1.15M | 1.25M |
| Total Liabilities | 6.46M | 8.04M | 10.85M | 19.92M | 19.80M | 17.65M |
| Stockholders Equity | 11.47M | -4.78M | -111.50K | -1.98M | 16.27M | 49.65M |
Cash Flow | ||||||
| Free Cash Flow | -15.88M | -21.31M | -31.50M | -28.85M | -30.18M | -22.65M |
| Operating Cash Flow | -15.87M | -21.31M | -31.46M | -28.42M | -29.92M | -22.65M |
| Investing Cash Flow | 617.18K | 3.13M | 12.45M | -3.43M | -261.37K | -5.72K |
| Financing Cash Flow | 26.31M | 11.21M | 20.55M | 9.90M | 18.36K | -93.64K |
Palatin Technologies Technical Analysis
Positive
16.05
Price Trends
20.15
Positive
19.36
Positive
14.00
Positive
Market Momentum
0.14
Negative
60.33
Neutral
91.52
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTN, the sentiment is Positive. The current price of 16.05 is below the 20-day moving average (MA) of 19.57, below the 50-day MA of 20.15, and above the 200-day MA of 14.00, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 60.33 is Neutral, neither overbought nor oversold. The STOCH value of 91.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTN.
Palatin Technologies Risk Analysis
Palatin Technologies disclosed 48 risk factors in its most recent earnings report. Palatin Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Palatin Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $6.80M | -0.89 | -71.27% | ― | -55.97% | -198.81% | |
47 Neutral | $9.19M | -2.34 | -97.58% | ― | 0.07% | 46.20% | |
46 Neutral | $12.78M | -0.89 | -107.58% | ― | ― | 77.90% | |
45 Neutral | $34.92M | -0.51 | -5515.09% | ― | 2461.02% | 87.54% | |
43 Neutral | $58.19M | -7.35 | -71.26% | ― | -20.00% | 62.69% | |
42 Neutral | $5.03M | -0.82 | -420.31% | ― | -10.30% | -36.45% |
* Healthcare Sector Average
PTN
Palatin Technologies
16.55
11.30
215.24%
IBIO
Ibio
1.55
0.82
112.91%
PHIO
Phio Pharmaceuticals
1.13
-0.73
-39.25%
BRTX
BioRestorative Therapies
0.20
-1.51
-88.48%
ADXN
Addex Therapeutics
6.70
-1.42
-17.49%
BOLT
Bolt Biotherapeutics
4.78
-2.22
-31.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.